Jump to content

Drilldown: Medicines

Choose a table:


Medicines > classes : 5HT1A activity than aripiprazole or Classic Psychedelic or Research material

Use the filters below to narrow your results.

generic:
brand:
None (141) · (none, never marketed) (1) · Delysid (historical, Sandoz, withdrawn 1965) (1) · O-DSMT (1) · Rexulti (1)
classes: (Click arrow to add another value)
mechanism:
5-HT2A agonist (27) · Monoamine releasing agent (9) · GABAA positive allosteric modulator (8) · CB1/CB2 agonist (7) · Dopamine/norepinephrine reuptake inhibitor (5) · Potent 5-HT2A agonist (5) · LSD analogue; 5-HT2A agonist (4) · Prodrug of LSD; 5-HT2A agonist (4) · Serotonin/norepinephrine/dopamine releasing agent (3) · Cathinone analogue; monoamine reuptake inhibitor (2) · Contains LSA (2) · Contains mescaline (2) · Dopamine and norepinephrine reuptake inhibitor (2) · NMDA antagonist (2) · Prodrug of GHB (2)
uses:
None (143) · No approved medical problem. Encountered as a designer/research benzodiazepine and, increasingly, as an adulterant in illicit opioid supplies. (1) · Schizophrenia (FDA-approved 2015). Adjunctive treatment of major depressive disorder (2015). '''Agitation associated with dementia due to Alzheimer disease''' (FDA-approved May 2023, first agent specifically approved for this problem). Investigational for PTSD (combined with sertraline). (1)
starting dose:
None (143) · No medical dose. Active recreational doses reported in the 0.5–1.5 mg range (similar potency to alprazolam). (1) · Schizophrenia: 1 mg PO daily × 4 days, then 2 mg daily × 3 days, then 4 mg daily. MDD adjunct: 0.5-1 mg daily, increase to 2 mg max. AD agitation: 0.5 mg daily, titrate to 2-3 mg daily. (1)
preparations:
None (143) · 0.25 mg, 0.5 mg, 1 mg, 2 mg, 3 mg, 4 mg tablets (1) · Illicit tablets ("bars"), powders, blotter, occasionally solutions. No pharmaceutical product exists. (1)
fda max:
None (143) · 4 mg/d (schizophrenia); 3 mg/d (AD agitation); 3 mg/d (MDD adjunct) (1) · N/A (never approved) (1)
routes:
None (142) · intranasal; rectal and IV reported. (1) · Oral (3) · sublingual (1)
onset:
None (142) · 30–60 minutes (1) · Weeks for psychosis/depression; AD agitation benefit emerges over weeks (1) · ~20–40 min PO; faster sublingual/intranasal. (1)
duration:
None (142) · 6–10 h subjective; full pharmacologic effect considerably longer. (1) · 8–12 hours (1) · Daily dosing (1)
halflife:
None (142) · 3–5 hours (1) · Estimated ~12–17 h (some sources cite up to ~21 h); active metabolites prolong effect. (1) · ~91 hours (1)
bioavailability:
None (142) · 70–90% (oral) (1) · Not formally characterized in humans. (1) · ~95% (1)
pregnancy:
None (142) · Avoid. Benzodiazepines are associated with neonatal sedation, floppy-infant syndrome, and withdrawal; teratogenic signal weak but non-zero. Designer benzo with no safety data, assume worst-case. (1) · Limited data; National Pregnancy Registry available (1) · Not established (1)
legal:
None (143) · Rx (1) · Schedule I (United States) (1)

Showing below up to 203 results in range #1 to #203.

View (previous 250 | next 250) (20 | 50 | 100 | 250 | 500)


View (previous 250 | next 250) (20 | 50 | 100 | 250 | 500)

Retrieved from "https://pharmacopedia.wiki/p/Special:Drilldown/Medicines"